These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 33753537)

  • 1. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial.
    De Vriese AS; Caluwé R; Van Der Meersch H; De Boeck K; De Bacquer D
    J Am Soc Nephrol; 2021 Jun; 32(6):1474-1483. PubMed ID: 33753537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study.
    De Vriese AS; Caluwé R; Pyfferoen L; De Bacquer D; De Boeck K; Delanote J; De Surgeloose D; Van Hoenacker P; Van Vlem B; Verbeke F
    J Am Soc Nephrol; 2020 Jan; 31(1):186-196. PubMed ID: 31704740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation.
    Karthikeyan G; Connolly SJ; Ntsekhe M; Benz A; Rangarajan S; Lewis G; Yun Y; Sharma SK; Maklady F; Elghamrawy AE; Kazmi K; Cabral TTJ; Dayi H; Changsheng M; Gitura BM; Avezum A; Zuhlke L; Lwabi P; Haileamlak A; Ogah O; Chillo P; Paniagua M; ElSayed A; Dans A; Gondwe-Chunda L; Molefe-Baikai OJ; Gonzalez-Hermosillo JA; Hakim J; Damasceno A; Kamanzi ER; Musuku J; Davletov K; Connolly K; Mayosi BM; Yusuf S;
    Am Heart J; 2020 Jul; 225():69-77. PubMed ID: 32474206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy.
    Gibson CM; Pinto DS; Chi G; Arbetter D; Yee M; Mehran R; Bode C; Halperin J; Verheugt FW; Wildgoose P; Burton P; van Eickels M; Korjian S; Daaboul Y; Jain P; Lip GY; Cohen M; Peterson ED; Fox KA
    Circulation; 2017 Jan; 135(4):323-333. PubMed ID: 27881555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study.
    Reinecke H; Engelbertz C; Bauersachs R; Breithardt G; Echterhoff HH; Gerß J; Haeusler KG; Hewing B; Hoyer J; Juergensmeyer S; Klingenheben T; Knapp G; Christian Rump L; Schmidt-Guertler H; Wanner C; Kirchhof P; Goerlich D
    Circulation; 2023 Jan; 147(4):296-309. PubMed ID: 36335915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS.
    Blin P; Dureau-Pournin C; Bénichou J; Cottin Y; Mismetti P; Abouelfath A; Lassalle R; Droz C; Moore N
    Am J Cardiovasc Drugs; 2020 Feb; 20(1):81-103. PubMed ID: 31254174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
    Vamos M; Cappato R; Marchlinski FE; Natale A; Hohnloser SH
    Europace; 2016 Dec; 18(12):1787-1794. PubMed ID: 26797248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.
    Ray WA; Chung CP; Stein CM; Smalley W; Zimmerman E; Dupont WD; Hung AM; Daugherty JR; Dickson A; Murray KT
    JAMA; 2021 Dec; 326(23):2395-2404. PubMed ID: 34932078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.
    Connolly SJ; Karthikeyan G; Ntsekhe M; Haileamlak A; El Sayed A; El Ghamrawy A; Damasceno A; Avezum A; Dans AML; Gitura B; Hu D; Kamanzi ER; Maklady F; Fana G; Gonzalez-Hermosillo JA; Musuku J; Kazmi K; Zühlke L; Gondwe L; Ma C; Paniagua M; Ogah OS; Molefe-Baikai OJ; Lwabi P; Chillo P; Sharma SK; Cabral TTJ; Tarhuni WM; Benz A; van Eikels M; Krol A; Pattath D; Balasubramanian K; Rangarajan S; Ramasundarahettige C; Mayosi B; Yusuf S;
    N Engl J Med; 2022 Sep; 387(11):978-988. PubMed ID: 36036525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.
    Cappato R; Ezekowitz MD; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca M; Vardas PE; Kirchhof P; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M; Hohnloser SH;
    Eur Heart J; 2014 Dec; 35(47):3346-55. PubMed ID: 25182247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study.
    Engelberger RP; Noll G; Schmidt D; Alatri A; Frei B; Kaiser WE; Kucher N
    Eur J Intern Med; 2015 Sep; 26(7):508-14. PubMed ID: 25935131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants.
    Ashley J; McArthur E; Bota S; Harel Z; Battistella M; Molnar AO; Jun M; Badve SV; Garg AX; Manuel D; Tanuseputro P; Wells P; Mavrakanas T; Rhodes E; Sood MM
    Am J Kidney Dis; 2020 Sep; 76(3):311-320. PubMed ID: 32333946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
    Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W
    Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and stage 5 chronic kidney disease under dialysis: A systematic review and meta-analysis of randomized controlled trials.
    de Lucena LA; Freitas MAA; Souza AKC; Silva CHA; Watanabe JMF; Guedes FL; Almeida JB; de Oliveira RA
    J Thromb Thrombolysis; 2024 Mar; 57(3):381-389. PubMed ID: 38281231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation.
    Blin P; Fauchier L; Dureau-Pournin C; Sacher F; Dallongeville J; Bernard MA; Lassalle R; Droz-Perroteau C; Moore N
    Stroke; 2019 Sep; 50(9):2469-2476. PubMed ID: 31390972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.
    Gibson CM; Mehran R; Bode C; Halperin J; Verheugt FW; Wildgoose P; Birmingham M; Ianus J; Burton P; van Eickels M; Korjian S; Daaboul Y; Lip GY; Cohen M; Husted S; Peterson ED; Fox KA
    N Engl J Med; 2016 Dec; 375(25):2423-2434. PubMed ID: 27959713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.